Stay updated with breaking news from Text View. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation to Bracco Imaging for its Vueway (gadopiclenol) contrast agent in the European Union
/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the...
/PRNewswire/ -- Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that...
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ with the indication of use for magnetic resonance imaging with contrast enhancement in adults and...
Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1 will become the...